Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Celcuity Inc.

Market Cap 4.29B 3.7B 3.41B 3.21B 6.02B 405B 6.07B 40.36B 15.71B 199B 16.12B 15.77B 688B P/E 2026 *
-21.8x
P/E 2027 * -188x
Enterprise Value 4.29B 3.7B 3.41B 3.21B 6.02B 405B 6.07B 40.36B 15.71B 199B 16.12B 15.77B 688B EV / Sales 2026 *
102x
EV / Sales 2027 * 11.2x
Free-Float
89.97%
Yield 2026 *
-
Yield 2027 * -
1 day+0.84%
1 week-0.22%
Current month-33.74%
1 month-36.05%
3 months-22.84%
6 months-11.11%
Current year-11.72%
1 week 85.59
Extreme 85.5934
91
1 month 83.77
Extreme 83.77
142.82
Current year 83.77
Extreme 83.77
151.02
1 year 11.28
Extreme 11.275
151.02
3 years 7.58
Extreme 7.575
151.02
5 years 4.81
Extreme 4.81
151.02
10 years 4.03
Extreme 4.03
151.02
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 64 01/01/2012
Chief Executive Officer 64 01/01/2012
Director of Finance/CFO 59 01/07/2017
Director TitleAgeSince
Chairman 64 01/01/2012
Director/Board Member 64 01/01/2012
Director/Board Member 67 01/02/2014
Date Insider Type Main position Quantity % Market Cap.
06-10Don

Director

-25,006 0.0540%
06-10Don

Director

-28,096 0.0607%
06-05Free

Director

1,530 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
+0.84%-0.22%+647.45%+719.83% 4.29B
+0.67%+1.26%+66.12%+118.11% 56.24B
+0.04%+1.20%+47.67%+36.75% 43.76B
+3.04%+7.05%-12.15%-18.06% 23.32B
+3.07%+7.15%-1.82%+392.25% 21.34B
+3.22%+2.94%+24.02%-34.00% 15.75B
+0.72%+2.17%+16.59%-37.49% 15.6B
+0.65%-0.27%+26.80%+174.70% 13.18B
+3.07%+5.43%+21.37% - 12.01B
+1.92%+2.43%+112.68%+232.59% 11.87B
Average +1.72%+2.82%+94.87%+176.07% 21.74B
Weighted average by Cap. +1.43%+2.90%+49.90%+113.14%

Financials

2026 *2027 *
Net sales 42.08M 36.3M 33.37M 31.41M 59.03M 3.97B 59.52M 396M 154M 1.95B 158M 155M 6.74B 383M 330M 304M 286M 537M 36.14B 542M 3.6B 1.4B 17.74B 1.44B 1.41B 61.36B
Net income -218M -188M -173M -163M -305M -20.55B -308M -2.05B -797M -10.08B -817M -800M -34.89B -34.95M -30.15M -27.72M -26.09M -49.02M -3.3B -49.44M -328M -128M -1.62B -131M -128M -5.6B
Net Debt - -
Logo Celcuity Inc.
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.
Employees
155
Date Price Change Volume
17/06/26 88.05 $ +0.84% 1,212,278
16/06/26 87.32 $ -1.04% 906,054
15/06/26 88.24 $ -0.35% 1,142,410
12/06/26 88.55 $ -1.05% 1,532,972
11/06/26 89.49 $ +1.42% 1,603,374
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
88.05USD
Average target price
161.09USD
Spread / Average Target
+82.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CELC Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!